Background-Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting DES use in patients at the highest risk for target vessel revascularization (TVR), we developed and validated a model to predict TVR. Methods and Results-Preprocedural clinical and angiographic data from 27 107 percutaneous coronary intervention hospitalizations between October 1, 2004, and September 30, 2007, in Massachusetts were used to develop prediction models for TVR at 1 year. Models were developed from a two-thirds random sample and validated in the remaining third. The overall rate of TVR was 7.6% (6.7% with DES, 11% with bare metal stents). Significant predictors of TVR included prior percutaneous coronary intervention, emergency or salvage percutaneous coronary intervention, prior coronary bypass surgery, peripheral vascular disease, diabetes mellitus, and angiographic characteristics. The model was superior to a 3-variable model of diabetes mellitus, stent diameter, and stent length (c statistic, 0.66 versus 0.60; PϽ0.001) and was well calibrated. The predicted number needed to treat with DES to prevent 1 TVR compared with bare metal stents ranged from 6 (95% confidence interval, 5.4 -7.6) to 80 (95% confidence interval, 62.7-116.3), depending on patients' clinical and angiographic factors. Conclusions-A predictive model using commonly collected variables can identify patients who may derive the greatest benefit in TVR reduction from DES. Whether use of the model improves the safety and cost-effectiveness of DES use should be tested prospectively. (Circulation. 2011;124:00-00.)
rospectively defining patients' risks before invasive procedures is critical for the rational application of technologies to improve outcomes. 1, 2 This principle is of particular importance when potential alternative treatment strategies are associated with a competing, but distinct, set of risks. The characterization of potential risks and benefits is also essential to improve the transparency and accuracy of informed consent.
Clinical Perspective on p •••
For patients undergoing percutaneous coronary intervention (PCI), drug-eluting stents (DES) significantly reduce the rate of restenosis of the target vessel compared with bare metal stents (BMS). [3] [4] [5] However, they require the prolonged use of thienopyridines to avoid the rare but potentially fatal complication of stent thrombosis and may have higher rates of very late stent thrombosis than BMS. 6 -8 In addition, DES are significantly more expensive than BMS, so the costeffectiveness of their use is dependent on the expected absolute reduction in restenosis for a given patient. 9 Collectively, these data support the preferential use of DES in patients at highest risk for restenosis. Although a number of prior studies have identified predictors of target vessel revascularization (TVR), they have a number of limitations that limit their use in guiding stent selection in routine practice, including derivation from restricted clinical trial patient populations, 10 incorporation of post-PCI data that can be obtained only after a stent has already been implanted, 11, 12 or use of predictors that are not typically or easily assessed. 13, 14 To improve the prospective stratification of patients' risks for TVR, predictive models that are limited to preprocedural clinical and angiographic data are required. By providing this information at the point of care, it may be possible to support the optimal use of DES and to engage patients in the decision-making process. Engaging patients in selecting stent type is particularly important because they will need to comply with long-term dual antiplatelet therapy if DES is used.
The goal of this study was to develop and validate a model to predict the likelihood of TVR after PCI with either DES or BMS within a large real-world population using variables commonly collected as part of the National Cardiovascular Data Registry (NCDR) CathPCI data collection instrument. This prediction model could then be used to derive the anticipated absolute risk reduction in TVR associated with DES use compared with BMS use and prospectively support clinical decision making.
Methods

Study Population
Since 2003, the Massachusetts Department of Public Health has systematically collected data on all PCI procedures performed at all acute care, nonfederal Massachusetts hospitals. The data are collected by trained hospital personnel using the NCDR CathPCI data collection instrument and are submitted electronically to the Massachusetts Data Analysis Center at Harvard Medical School. Selected covariates and outcomes are audited and adjudicated as previously described. 15 To obtain subsequent TVR rates, we linked the index PCI to data on all subsequent revascularization procedures longitudinally from the Massachusetts Data Analysis Center and to hospitaldischarge billing data collected by the Massachusetts Division of Health Care Finance and Policy. 16 We initially identified all PCI admissions between October 1, 2004, and September 30, 2007 . For admissions in which multiple PCIs were performed, we included only the first PCI in the analysis. We subsequently excluded PCI admissions for the following reasons: no stent deployed (nϭ3054), both DES and BMS stents used (nϭ1648), inability to link data or patient was not a Massachusetts resident (nϭ4394), and missing data (nϭ98). We additionally excluded those patients who received devices Ͻ2.25 and Ͼ4 mm in diameter, for which DES were not available (nϭ708).
We next developed a propensity score model to predict the log odds of DES (versus BMS) use, conditioned on 46 demographic and clinical variables, and plotted the frequency distribution of propensity scores by stent type. To identify a sample of patients who were eligible for both stent types, we excluded procedures falling into regions of nonoverlap in propensity scores, identified as having a logit of the predicted probability of receiving DES Ͻ0 or Ͼ3 (nϭ96 BMS and 769 DES patients). The remaining 27 107 PCI admissions were included in the analysis and represent a group for whom either stent type might be reasonably considered.
Definitions
The primary outcome of interest was the occurrence of TVR within 12 months of the index procedure. We defined TVR as PCI performed in a vessel treated during the index procedure or any coronary artery bypass graft surgery performed after the index procedure. 16 Definitions for the data elements for version 3.04 of the CathPCI registry are available at http://www.ncdr.com/WebNCDR/Elements.aspx, and definitions for all variables retained in final risk prediction models can be found in Table I of the online-only Data Supplement. We identified a list of variables to be included in the initial multivariable model to predict TVR based on clinical relevance. These included sociodemographic information (age, sex, race/ethnicity, insurance status, and smoking status), medical history (body mass index, hypertension, diabetes mellitus, glomerular filtration rate, hemodialysis), cardiovascular history (prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, prior PCI, prior coronary artery bypass graft, prior congestive heart failure, and Canadian Cardiovascular Society/New York Heart Association classification), and clinical status variables at admission (disease presentation [ST-segment-elevation myocardial infarction, non-STsegment-elevation myocardial infarction, unstable angina, stable angina or atypical chest pain, no chest pain] and PCI status [elective, urgent, emergent/salvage]). Estimated glomerular filtration rate was calculated from the abbreviated Modification of Diet in Renal Disease formula based on creatinine assessed at the time of admission. 17 We additionally identified a list of relevant angiographic variables, including minimum stent diameter (Ͻ3 versus Ն3 mm), total stent length (Ͻ30 versus Ն30 mm), bifurcation lesion, previously treated lesion, lesion within saphenous vein graft, treated lesion within left anterior descending artery, multivessel disease (Ն2 vessels with Ն70% stenosis), and number of treated lesions. Dichotomization for stent length was selected after inclusion of a categorical variable revealed a cutoff value (30 mm) at which the multivariable adjusted odds of TVR increased substantially. Stent diameter was dichotomized to retain meaningful numbers of patients above and below the cutoff value and to improve the ease of subsequent implementation of the model. Stent diameter and length were included as estimates of lesion length and reference diameter because these values were not available. In addition, these stent characteristics can be readily predicted from the preprocedural angiogram and used to inform stent selection.
Statistical Analysis
We first examined bivariate associations of TVR with variables identified on the basis of their clinical relevance. Next, multivariable logistic regression was performed in a randomly selected two-thirds sample (developmental cohort) to identify predictors of TVR. In the first model, we considered only clinical variables, without inclusion of angiographic variables, to support preprocedural discussions with patients regarding the benefits of alternative stent types. Backward elimination of variables was performed until the adjusted R 2 of the model reached 95% of that of the full model. 18 We then generated a similar model including angiographic variables (the full model). For all models, an indicator variable for DES versus BMS was used. Although recent data suggest potential differences in outcomes among DES types, these differences are small in magnitude relative to differences in TVR between DES and BMS. 19 Because the purpose of our model was to help inform the DES versus BMS decision, we elected to group all DES together instead of analyzing each DES type separately. A number of interaction terms were considered to evaluate the possibility that the strength of the association of clinical and angiographic characteristics with TVR might differ for BMS-and DES-treated patients, including interactions of stent type with age, diabetes mellitus, renal function, clinical presentation, saphenous vein graft intervention, vessel location, stent length, and stent diameter. However, none of these interactions were found to be significant and thus were not included in the models.
For validation, we applied coefficients of the models to the remaining one-third sample (validation cohort). Model discrimination was assessed with the c index, and model calibration was assessed by examining predicted versus observed rates of TVR within deciles of predicted TVR risk and testing the difference with the Hosmer-Lemeshow 2 test. Overfitting statistics were estimated as described by Harrell. 18 After the models were found to perform similarly in the developmental and validation cohorts, final nonangiographic and angiographic models using the entire study sample (merged developmental and validation cohorts) were generated. We calculated the integrated discrimination improvement (IDI) to assess the improvement in discrimination of the full model including angiographic characteristics compared with the nonangiographic model. 20 The IDI provides a quantitative summary that measures the average absolute improvement in individual risk predictions that results from the inclusion of additional variables to a prediction model.
Prior studies have advocated using as few as 3 variables to predict restenosis: diabetes mellitus, lesion/stent length, and vessel/stent diameter. 4, 10 We therefore also compared the improvement in discrimination of the full model compared with a more parsimonious model accounting for stent type and these 3 variables as measured by the c statistic and IDI.
To assess the distribution of predicted reduction in TVR associated with DES use, we generated predicted probabilities of TVR assuming PCI with either DES or BMS by individually applying the clinical and angiographic profile of each patient in the study population to the models. We then subtracted the predicted probability of TVR with DES from that with BMS to derive the predicted TVR reduction associated with DES for each patient in the sample and calculated the estimated number needed to treat (NNT).
To quantify our uncertainty with both the predicted TVR reduction and the NNT estimates, we used resampling procedures implemented through bootstrapping. Specifically, we sampled all admissions with replacement, re-estimated the logistic regression model, and computed summaries of both the predicted reduction in TVR with DES and the NNT. These summaries included the minimum, maximum, mean, and median benefit (and corresponding NNT). We repeated this 1000 times and computed the mean of the various summaries over the 1000 samples. We also constructed bootstrap 95% confidence intervals (CIs) for these selected summaries by determining the 2.5th and the 97.5th percentiles of the empirical distribution. All analyses were conducted with SAS version 9.2.
Results
Of the 27 107 PCI admissions examined, 21 933 (80.9%) underwent PCI with DES, and the remaining 5174 (19.1%) received BMS. Baseline clinical and angiographic characteristics, stratified by the occurrence of TVR by 1 year, are shown in Tables 1 and 2 . By 1 year after the index PCI, TVR occurred in 7.6% of patients overall (6.7% of DES patients and 11.0% of BMS patients). Bivariate analyses suggested that patients who had TVR were younger, were more often diabetic, and had higher rates of prior myocardial infarction, peripheral vascular disease, prior PCI, and prior coronary artery bypass graft. Patients with TVR more often had multivessel disease and had received stents with smaller diameters and longer lengths at the index procedure. The mortality rates at 1 year for patients with and without TVR were similar (5.3% versus 5.2%; Pϭ0.78).
Model Development and Validation
The nonangiographic and full models had c statistics of 0.61 and 0.66, respectively, in the developmental models. Model discrimination when applied to the validation sample was similar (c statistic, 0.64 and 0.65 for the nonangiographic and angiographic models, respectively). A comparison of observed TVR rates at 1 year in the validation sample and the predicted risk of TVR demonstrated good calibration of both the nonangiographic (Hosmer-Lemeshow Pϭ0.65) and angiographic (Hosmer-Lemeshow Pϭ0.90) models without evidence of overfitting ( Figure 1 ).
Final Nonangiographic and Full Models
Because models showed similar discrimination and similar calibration in both the developmental and validation samples, final models were generated with the entire study sample. Beta weights and standard errors for models are included in (Figure 2) .
Angiographic variables retained in the full model included having Ն2 vessels with Ն70% stenosis, the number of lesions treated, stent diameter Ն3.0 mm, and total stent length Ն30 mm. All nonangiographic variables except prior coronary artery bypass graft were also retained in the full model. The addition of angiographic variables further improved model discrimination (c statistic, 0.62 for nonangiographic model in the complete cohort compared with 0.66 for the full model; IDI, 0.010; PϽ0.001). This IDI value means that the percent of variation in TVR risk explained by the model increased by 1.0% in absolute terms in the full model compared with the nonangiographic model. Treatment with DES continued to be associated with a significant reduction in 1-year TVR (odds ratio, 0.53; 95% CI, 0.47-0.59). There were no statistically significant interactions in either model.
Comparison of Final Model With Usual Practice
Given that current practice emphasizes 3 factors, diabetes mellitus, lesion/stent length, and vessel/stent diameter, 4, 10 in considering TVR risk, we compared the full model with the discrimination of these 3 variables alone (in addition to stent type). We found that model discrimination improved significantly (c statistic, 0.60 versus 0.66; IDI, 0.013; PϽ0.001), supporting the potential for the new model to improve clinicians' estimates of TVR risk compared with the prevailing standard.
Predicted Target Vessel Revascularization and Restenosis Benefit With Drug-Eluting Stents
The distribution of predicted rates of TVR from the full model assuming use of BMS varied broadly, from 2.7% to 57.4% (Figure 3) . These values corresponded to absolute TVR reductions associated with DES use ranging from 1.2% (95% CI, 0.9 -1.6) to 15.9% (95% CI, 13.0 -18.4), with an interquartile range of 3.5% to 6.3%. Similarly, the predicted NNT to prevent 1 TVR with DES compared with BMS ranged from as few as 6 patients (95% CI, 5.4 -7.6) to as high as 80 patients (95% CI, 62.7-116.3), depending on clinical and angiographic characteristics. Similar results were observed for the nonangiographic model, with the NNT ranging from 8 (95% CI, 6.6 -10.3) to 61 (95% CI, 46.2-86.4).
Discussion
In a large statewide registry of patients undergoing PCI, we found that TVR at 1 year occurred in 6.7% of patients undergoing PCI with DES and 11.0% of patients undergoing PCI with BMS. Using variables routinely collected as part of the NCDR CathPCI instrument, we developed and validated parsimonious models to predict TVR using both clinical and angiographic variables. We found that the predicted reduction in TVR for DES compared with BMS varied broadly, depending on patient characteristics. The factors associated with TVR in our study were similar to those found in previous studies examining predictors of TVR, including prior PCI, diabetes mellitus, longer stent length, and smaller stent diameter, although we identified other important variables that further improved risk stratification. [21] [22] [23] The addition of angiographic variables significantly improved overall discrimination of the models. Although prior studies have found strong associations of angiographic variables with restenosis, they have typically not assessed the incremental improvement in discrimination that resulted from the addition of these variables to nonangiographic clinical characteristics, as we have done in this study. 12,24 -26 Moreover, we found a significant improvement in discrimination of TVR risk compared with the current clinical practice of relying solely on patients' diabetes status, lesion/stent length, and vessel/stent diameter, underscoring the potential clinical utility of our model.
Our study differs from prior work in a number of important ways. First, because all nonfederal hospitals in Massachusetts are required to participate in the registry, the results are generated from a population-based sample of patients undergoing PCI in routine clinical practice without being subjected to the selection biases that occur with clinical trials or volunteer registries. In addition, the model is built on vari- ables commonly collected as part of the NCDR CathPCI instrument, which is currently used in Ͼ1000 hospitals across all 50 US states, making it widely applicable and potentially easily integrated into routine care at these facilities. [27] [28] [29] Finally, our analysis was performed during a time period that included a large number of both BMS and DES patients, allowing the precise estimation of expected TVR reduction with DES across the entire spectrum of clinical profiles.
As expected, the use of DES was associated with a significant decrease in the occurrence of TVR compared with BMS. None of the interaction terms we explored to examine whether the benefit of DES was modified by clinical factors were found to be significant, so the relative risk reduction in TVR (Ϸ45%) was constant for all patients in the study. However, the absolute risk reduction differed substantially between patients on the basis of their clinical profiles, with the NNT to prevent 1 TVR ranging from 6 to 80, depending on patient characteristics.
Such differences in absolute risk reduction create the opportunity to prospectively identify and use DES in patients who stand to derive the greatest benefit from DES while considering BMS in patients with low anticipated benefit, given the added bleeding risk and costs associated with DES and its requirement for prolonged dual antiplatelet therapy. In fact, when the risk of restenosis with BMS is Յ10%, the NNT exceeds 25, meaning that Ͼ25 patients would need to be treated with DES to avoid a single repeat PCI procedure for restenosis ( Figure 4 ). Prior economic analyses have suggested that a TVR rate with BMS of Ͻ11% is associated with an increase in society-based costs of more than $10 000 to prevent 1 repeat procedure and would not be considered a cost-effective use of DES. 9 In our sample, Ͼ45% of patients undergoing PCI had a predicted rate of restenosis with BMS that was less than this threshold, 78.6% of whom received DES. Because our model specifically used variables obtainable before stent implantation, it could be used prospectively to help guide physicians in stent selection and to apprise patients more accurately of the risks and benefits of the different stent choices. Such a use of the model would enable greater and more informed patient participation in clinical decisions, a priority for the Institute of Medicine's goals for improving the quality of care. 30 In fact, our group is currently testing the impact of prospective risk stratification, through individualized informed consent documents imbedded with this risk model, on patient and physician decision making and long-term compliance with dual antiplatelet therapy. 27 Our analyses should be interpreted in the context of several potential limitations. Although we included a large number of clinically relevant variables in our models, the discrimination of the models was modest. Whereas our model discrimination compares favorably with other reported models, 23 including those that incorporate post-PCI variables, 31 there may be unobserved procedural (eg, quality of stent deployment), biological (eg, genetic predisposition), or social (eg, access to care, compliance with therapy) factors that are associated with TVR and not accounted for in these models. In addition, because the goal of our study was to produce a model that could be prospectively used to guide decisions during PCI, we did not incorporate variables that could be ascertained only after completion of the procedure such as adequate stent deployment, apposition, or coronary dissection that might further improve model discrimination. Because inherent uncertainty exists for the application of prediction models to any individual patient, estimates of predicted TVR risk are meant to enhance but not replace clinical judgment. To highlight this uncertainty, results of predicted TVR risk are presented with associated 95% CIs when the publicly available Web-based calculator is used, an advantage over using common risk scores, which do not account for imprecision in estimates. Next, our results are based on prospectively collected observational data, and thus are vulnerable to the omission of unobserved risk factors that may confound the choice of stent type with patient illness. Although the model was found to be well calibrated in both the DES-and BMS-treated patients, regression estimates were generated primarily from a DES population, and may therefore be optimized for this subgroup. Because we found no significant interactions between stent type and other covariates for the TVR outcome, we derived estimates of absolute risk reduction in TVR for DES that are based on this assumption. Next, we captured only data on PCI that occurred within nonfederal Massachusetts hospitals, which may limit some of the generalizability of our findings. In addition, there might be circumstances in which one stent choice over another was clearly clinically indicated, although we restricted the sample to patients who were apparently eligible for both types of stents. In using TVR as our primary outcome, we were not able to determine whether revascularization of the target vessel was due to restenosis of the index lesion or to new coronary lesions within the same vessel. This outcome may also depend on a variety of factors, including patient and physician perception of benefit. However, we believe that TVR is an appropriate patient-oriented outcome compared with angiographically defined restenosis, which may not be functionally significant.
Conclusions
We developed and validated a predictive model to predict the occurrence of TVR after PCI that allows the quantification of the anticipated benefit of PCI with DES compared with BMS in a large community-based population. The prospective use of individualized assessments of patient benefits may support the safer and more cost-effective application of this technology. Moreover, prospectively informing patients of the benefits of a DES may support shared medical decision making and improve patients' understanding of the need for longterm dual antiplatelet therapy within the context of their reduced risk for TVR after DES. 
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CLINICAL PERSPECTIVE
Drug-eluting stents for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting drug-eluting stent use in patients at the highest risk for target vessel revascularization, we developed and validated a model to predict target vessel revascularization from a contemporary population-based registry in Massachusetts based on commonly collected clinical and angiographic variables that are obtainable before percutaneous coronary intervention. The ability of the model to discriminate 1-year target vessel revascularization risk among percutaneous coronary intervention patients was significantly better than a simpler model based on the presence of diabetes mellitus, stent length, and stent diameter (c statistic, 0.66 versus 0.60; integrated discrimination index, 0.013; PϽ0.001). The predicted reduction in target vessel revascularization associated with drug-eluting stents use ranged from as little as 1.2% (95% confidence interval, 0.9 -1.6) to 15.9% (95% confidence interval, 13.0 -18.4), depending on patient characteristics. Because the predicted benefit associated with drug-eluting stents varies broadly among patients, this predictive model may be used to support the optimal use of drug-eluting stents in a prospective fashion and to engage patients in the decision-making process before coronary intervention. Tables   Supplemental Table 1 
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Patient has cardiac disease resulting in slight limitation of ordinary physician activity. Patient is comfortable at rest. Ordinary physical activity such as walking more than two blocks or climbing more than one flight of stairs results in limiting symptoms (e.g., fatigue, palpitation, dyspnea, or anginal pain).
III
Patient has cardiac disease resulting in marked limitation of physical activity. Patient is comfortable at rest. Less than ordinary physical activity (e.g., walking one to two level blocks or climbing one flight of stairs) causes fatigue, palpitation, dyspnea, or anginal pain.
IV
Patient has dyspnea at rest that increases with any physical activity. Patient has cardiac disease resulting in inability to perform any physical activity without discomfort. Symptoms may be present even at rest. rospectively defining patients' risks before invasive procedures is critical for the rational application of technologies to improve outcomes. 1, 2 This principle is of particular importance when potential alternative treatment strategies are associated with a competing, but distinct, set of risks. The characterization of potential risks and benefits is also essential to improve the transparency and accuracy of informed consent.
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Methods
Study Population
Since 2003, the Massachusetts Department of Public Health has systematically collected data on all PCI procedures performed at all acute care, nonfederal Massachusetts hospitals. The data are collected by trained hospital personnel using the NCDR CathPCI data collection instrument and are submitted electronically to the Massachusetts Data Analysis Center at Harvard Medical School. Selected covariates and outcomes are audited and adjudicated as previously described. 15 To obtain subsequent TVR rates, we linked the index PCI to data on all subsequent revascularization procedures longitudinally from the Massachusetts Data Analysis Center and to hospitaldischarge billing data collected by the Massachusetts Division of Health Care Finance and Policy. 16 We initially identified all PCI admissions between October 1, 2004, and September 30, 2007. For admissions in which multiple PCIs were performed, we included only the first PCI in the analysis. We subsequently excluded PCI admissions for the following reasons: no stent deployed (n�3054), both DES and BMS stents used (n�1648), inability to link data or patient was not a Massachusetts resident (n�4394), and missing data (n�98). We additionally excluded those patients who received devices �2.25 and �4 mm in diameter, for which DES were not available (n�708).
We next developed a propensity score model to predict the log odds of DES (versus BMS) use, conditioned on 46 demographic and clinical variables, and plotted the frequency distribution of propensity scores by stent type. To identify a sample of patients who were eligible for both stent types, we excluded procedures falling into regions of nonoverlap in propensity scores, identified as having a logit of the predicted probability of receiving DES �0 or �3 (n�96 BMS and 769 DES patients). The remaining 27 107 PCI admissions were included in the analysis and represent a group for whom either stent type might be reasonably considered.
Definitions
The primary outcome of interest was the occurrence of TVR within 12 months of the index procedure. We defined TVR as PCI performed in a vessel treated during the index procedure or any coronary artery bypass graft surgery performed after the index procedure. 16 Definitions for the data elements for version 3.04 of the CathPCI registry are available at http://www.ncdr.com/WebNCDR/Elements.aspx, and definitions for all variables retained in final risk prediction models can be found in Table I of the online-only Data Supplement. We identified a list of variables to be included in the initial multivariable model to predict TVR based on clinical relevance. These included sociodemographic information (age, sex, race/ethnicity, insurance status, and smoking status), medical history (body mass index, hypertension, diabetes mellitus, glomerular filtration rate, hemodialysis), cardiovascular history (prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, prior PCI, prior coronary artery bypass graft, prior congestive heart failure, and Canadian Cardiovascular Society/New York Heart Association classification), and clinical status variables at admission (disease presentation [ST-segment-elevation myocardial infarction, non-STsegment-elevation myocardial infarction, unstable angina, stable angina or atypical chest pain, no chest pain] and PCI status [elective, urgent, emergent/salvage]). Estimated glomerular filtration rate was calculated from the abbreviated Modification of Diet in Renal Disease formula based on creatinine assessed at the time of admission. 17 We additionally identified a list of relevant angiographic variables, including minimum stent diameter (�3 versus �3 mm), total stent length (�30 versus �30 mm), bifurcation lesion, previously treated lesion, lesion within saphenous vein graft, treated lesion within left anterior descending artery, multivessel disease (�2 vessels with �70% stenosis), and number of treated lesions. Dichotomization for stent length was selected after inclusion of a categorical variable revealed a cutoff value (30 mm) at which the multivariable adjusted odds of TVR increased substantially. Stent diameter was dichotomized to retain meaningful numbers of patients above and below the cutoff value and to improve the ease of subsequent implementation of the model. Stent diameter and length were included as estimates of lesion length and reference diameter because these values were not available. In addition, these stent characteristics can be readily predicted from the preprocedural angiogram and used to inform stent selection.
Statistical Analysis
For validation, we applied coefficients of the models to the remaining one-third sample (validation cohort). Model discrimination was assessed with the c index, and model calibration was assessed by examining predicted versus observed rates of TVR within deciles of predicted TVR risk and testing the difference with the Hosmer-Lemeshow � 2 test. Overfitting statistics were estimated as described by Harrell. 18 After the models were found to perform similarly in the developmental and validation cohorts, final nonangiographic and angiographic models using the entire study sample (merged developmental and validation cohorts) were generated. We calculated the integrated discrimination improvement (IDI) to assess the improvement in discrimination of the full model including angiographic characteristics compared with the nonangiographic model. 20 The IDI provides a quantitative summary that measures the average absolute improvement in individual risk predictions that results from the inclusion of additional variables to a prediction model.
Results
Of the 27 107 PCI admissions examined, 21 933 (80.9%) underwent PCI with DES, and the remaining 5174 (19.1%) received BMS. Baseline clinical and angiographic characteristics, stratified by the occurrence of TVR by 1 year, are shown in Tables 1 and 2 . By 1 year after the index PCI, TVR occurred in 7.6% of patients overall (6.7% of DES patients and 11.0% of BMS patients). Bivariate analyses suggested that patients who had TVR were younger, were more often diabetic, and had higher rates of prior myocardial infarction, peripheral vascular disease, prior PCI, and prior coronary artery bypass graft. Patients with TVR more often had multivessel disease and had received stents with smaller diameters and longer lengths at the index procedure. The mortality rates at 1 year for patients with and without TVR were similar (5.3% versus 5.2%; P�0.78).
Model Development and Validation
The nonangiographic and full models had c statistics of 0.61 and 0.66, respectively, in the developmental models. Model discrimination when applied to the validation sample was similar (c statistic, 0.64 and 0.65 for the nonangiographic and angiographic models, respectively). A comparison of observed TVR rates at 1 year in the validation sample and the predicted risk of TVR demonstrated good calibration of both the nonangiographic (Hosmer-Lemeshow P�0.65) and angiographic (Hosmer-Lemeshow P�0.90) models without evidence of overfitting (Figure 1 ).
Final Nonangiographic and Full Models
Because models showed similar discrimination and similar calibration in both the developmental and validation samples, MI indicates myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; CCS/NYHA, Canadian Cardiovascular Society/New York Heart Association; and STEMI, ST-elevation myocardial infarction.
final models were generated with the entire study sample. Beta weights and standard errors for models are included in Table II of the online-only Data Supplement, and a Webbased calculator that enables the clinical use of this model is available at http://www.massdac.org/riskcalc_revasc. Within the nonangiographic model, DES was associated with a significant decrease in 1-year TVR compared with BMS (odds ratio, 0.57; 95% CI, 0.52-0.64). The variables retained in the nonangiographic model were the use of DES, age, diabetes mellitus, peripheral vascular disease, hypertension, prior PCI, prior coronary artery bypass graft, admission symptoms, Canadian Cardiovascular Society/New York Heart Association class, and PCI indication (Figure 2) .
Angiographic variables retained in the full model included having �2 vessels with �70% stenosis, the number of lesions treated, stent diameter �3.0 mm, and total stent length �30 mm. All nonangiographic variables except prior coronary artery bypass graft were also retained in the full model. The addition of angiographic variables further improved model discrimination (c statistic, 0.62 for nonangiographic model in the complete cohort compared with 0.66 for the full model; IDI, 0.010; P�0.001). This IDI value means that the percent of variation in TVR risk explained by the model increased by 1.0% in absolute terms in the full model compared with the nonangiographic model. Treatment with DES continued to be associated with a significant reduction in 1-year TVR (odds ratio, 0.53; 95% CI, 0.47-0.59). There were no statistically significant interactions in either model.
Comparison of Final Model With Usual Practice
Given that current practice emphasizes 3 factors, diabetes mellitus, lesion/stent length, and vessel/stent diameter, 4, 10 in considering TVR risk, we compared the full model with the discrimination of these 3 variables alone (in addition to stent type). We found that model discrimination improved significantly (c statistic, 0.60 versus 0.66; IDI, 0.013; P�0.001), supporting the potential for the new model to improve clinicians' estimates of TVR risk compared with the prevailing standard.
Predicted Target Vessel Revascularization and Restenosis Benefit With Drug-Eluting Stents
Discussion
Our study differs from prior work in a number of important ways. First, because all nonfederal hospitals in Massachusetts are required to participate in the registry, the results are generated from a population-based sample of patients undergoing PCI in routine clinical practice without being subjected to the selection biases that occur with clinical trials or volunteer registries. In addition, the model is built on vari- ables commonly collected as part of the NCDR CathPCI instrument, which is currently used in �1000 hospitals across all 50 US states, making it widely applicable and potentially easily integrated into routine care at these facilities. [27] [28] [29] Finally, our analysis was performed during a time period that included a large number of both BMS and DES patients, allowing the precise estimation of expected TVR reduction with DES across the entire spectrum of clinical profiles.
As expected, the use of DES was associated with a significant decrease in the occurrence of TVR compared with BMS. None of the interaction terms we explored to examine whether the benefit of DES was modified by clinical factors were found to be significant, so the relative risk reduction in TVR (�45%) was constant for all patients in the study. However, the absolute risk reduction differed substantially between patients on the basis of their clinical profiles, with the NNT to prevent 1 TVR ranging from 6 to 80, depending on patient characteristics.
Such differences in absolute risk reduction create the opportunity to prospectively identify and use DES in patients who stand to derive the greatest benefit from DES while considering BMS in patients with low anticipated benefit, given the added bleeding risk and costs associated with DES and its requirement for prolonged dual antiplatelet therapy. In fact, when the risk of restenosis with BMS is �10%, the NNT exceeds 25, meaning that �25 patients would need to be treated with DES to avoid a single repeat PCI procedure for restenosis (Figure 4 ). Prior economic analyses have suggested that a TVR rate with BMS of �11% is associated with an increase in society-based costs of more than $10 000 to prevent 1 repeat procedure and would not be considered a cost-effective use of DES. 9 In our sample, �45% of patients undergoing PCI had a predicted rate of restenosis with BMS that was less than this threshold, 78.6% of whom received DES. Because our model specifically used variables obtainable before stent implantation, it could be used prospectively to help guide physicians in stent selection and to apprise patients more accurately of the risks and benefits of the different stent choices. Such a use of the model would enable greater and more informed patient participation in clinical decisions, a priority for the Institute of Medicine's goals for improving the quality of care. 30 In fact, our group is currently testing the impact of prospective risk stratification, through individualized informed consent documents imbedded with this risk model, on patient and physician decision making and long-term compliance with dual antiplatelet therapy. 27 Our analyses should be interpreted in the context of several potential limitations. Although we included a large number of clinically relevant variables in our models, the discrimination of the models was modest. Whereas our model discrimination compares favorably with other reported models, 23 including those that incorporate post-PCI variables, 31 there may be unobserved procedural (eg, quality of stent deployment), biological (eg, genetic predisposition), or social (eg, access to care, compliance with therapy) factors that are associated with TVR and not accounted for in these models. In addition, because the goal of our study was to produce a model that could be prospectively used to guide decisions during PCI, we did not incorporate variables that could be ascertained only after completion of the procedure such as adequate stent deployment, apposition, or coronary dissection that might further improve model discrimination. Because inherent uncertainty exists for the application of prediction models to any individual patient, estimates of predicted TVR risk are meant to enhance but not replace clinical judgment. To highlight this uncertainty, results of predicted TVR risk are presented with associated 95% CIs when the publicly available Web-based calculator is used, an advantage over using common risk scores, which do not account for imprecision in estimates. Next, our results are based on prospectively collected observational data, and thus are vulnerable to the omission of unobserved risk factors that may confound the choice of stent type with patient illness. Although the model was found to be well calibrated in both the DES-and BMS-treated patients, regression estimates were generated primarily from a DES population, and may therefore be optimized for this subgroup. Because we found no significant interactions between stent type and other covariates for the TVR outcome, we derived estimates of absolute risk reduction in TVR for DES that are based on this assumption. Next, we captured only data on PCI that occurred within nonfederal Massachusetts hospitals, which may limit some of the generalizability of our findings. In addition, there might be circumstances in which one stent choice over another was clearly clinically indicated, although we restricted the sample to patients who were apparently eligible for both types of stents. In using TVR as our primary outcome, we were not able to determine whether revascularization of the target vessel was due to restenosis of the index lesion or to new coronary lesions within the same vessel. This outcome may also depend on a variety of factors, including patient and physician perception of benefit. However, we believe that TVR is an appropriate patient-oriented outcome compared with angiographically defined restenosis, which may not be functionally significant.
Conclusions
We developed and validated a predictive model to predict the occurrence of TVR after PCI that allows the quantification of the anticipated benefit of PCI with DES compared with BMS in a large community-based population. The prospective use of individualized assessments of patient benefits may support the safer and more cost-effective application of this technology. Moreover, prospectively informing patients of the benefits of a DES may support shared medical decision making and improve patients' understanding of the need for longterm dual antiplatelet therapy within the context of their reduced risk for TVR after DES.
